

Paul M Mckie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7190412/publications.pdf>

Version: 2024-02-01

43
papers

2,455
citations

236833

25
h-index

315616

38
g-index

45
all docs

45
docs citations

45
times ranked

3059
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. <i>Nature Medicine</i> , 2019, 25, 70-74.	15.2	686
2	Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide. <i>Hypertension</i> , 2006, 47, 874-880.	1.3	150
3	The Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide for Death and Cardiovascular Events in Healthy Normal and Stage A/B Heart Failure Subjects. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2140-2147.	1.2	114
4	The Aging Heart, Myocardial Fibrosis, and its Relationship to Circulating C-Type Natriuretic Peptide. <i>Hypertension</i> , 2011, 57, 201-207.	1.3	95
5	B-Type Natriuretic Peptide and Survival in Hypertrophic Cardiomyopathy. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2456-2460.	1.2	92
6	A Genetic Variant of the Atrial Natriuretic Peptide Gene Is Associated With Cardiometabolic Protection in the General Community. <i>Journal of the American College of Cardiology</i> , 2011, 58, 629-636.	1.2	91
7	Corin Is Present in the Normal Human Heart, Kidney, and Blood, with Pro-B-Type Natriuretic Peptide Processing in the Circulation. <i>Clinical Chemistry</i> , 2011, 57, 40-47.	1.5	91
8	B-Type Natriuretic Peptide as a Biomarker Beyond Heart Failure: Speculations and Opportunities. <i>Mayo Clinic Proceedings</i> , 2005, 80, 1029-1036.	1.4	83
9	Human Hypertension Is Characterized by a Lack of Activation of the Antihypertensive Cardiac Hormones ANP and BNP. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1558-1565.	1.2	82
10	The Fragility Index: a <i>P</i> -value in sheep's clothing?. <i>European Heart Journal</i> , 2017, 38, ehw495.	1.0	72
11	Impaired Natriuretic and Renal Endocrine Response to Acute Volume Expansion in Pre-Clinical Systolic and Diastolic Dysfunction. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2095-2103.	1.2	70
12	NT-proBNP. <i>Journal of the American College of Cardiology</i> , 2016, 68, 2437-2439.	1.2	69
13	Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1267.	3.0	66
14	Pro-B-Type Natriuretic Peptide ¹⁻¹⁰⁸ Circulates in the General Community. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1386-1395.	1.2	65
15	Oral Human Brain Natriuretic Peptide Activates Cyclic Guanosine 3',5'-Monophosphate and Decreases Mean Arterial Pressure. <i>Circulation</i> , 2005, 112, 836-840.	1.6	63
16	A Human Atrial Natriuretic Peptide Gene Mutation Reveals a Novel Peptide With Enhanced Blood Pressure-Lowering, Renal-Enhancing, and Aldosterone-Suppressing Actions. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1024-1032.	1.2	58
17	Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006, 291, H1529-H1535.	1.5	54
18	Predictive Utility of Atrial, N-Terminal Pro-Atrial, and N-Terminal Pro-B-Type Natriuretic Peptides for Mortality and Cardiovascular Events in the General Community: A 9-Year Follow-up Study. <i>Mayo Clinic Proceedings</i> , 2011, 86, 1154-1160.	1.4	54

#	ARTICLE	IF	CITATIONS
19	CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart. PLoS ONE, 2012, 7, e52422.	1.1	54
20	High-Sensitivity Troponin I and Amino-Terminal Pro-B-Type Natriuretic Peptide Predict Heart Failure and Mortality in the General Population. Clinical Chemistry, 2014, 60, 1225-1233.	1.5	49
21	A Novel Atrial Natriuretic Peptide Based Therapeutic in Experimental Angiotensin II Mediated Acute Hypertension. Hypertension, 2010, 56, 1152-1159.	1.3	40
22	Circulating C-Type Natriuretic Peptide and Its Relationship to Cardiovascular Disease in the General Population. Hypertension, 2015, 65, 1187-1194.	1.3	35
23	CD-NP: An Innovative Designer Natriuretic Peptide Activator of Particulate Guanylyl Cyclase Receptors for Cardiorenal Disease. Current Heart Failure Reports, 2010, 7, 93-99.	1.3	33
24	Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging. American Journal of Physiology - Renal Physiology, 2011, 301, F943-F952.	1.3	32
25	M-Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics. Journal of the American Heart Association, 2014, 3, e000206.	1.6	30
26	M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy. Current Hypertension Reports, 2012, 14, 62-69.	1.5	23
27	Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. European Journal of Heart Failure, 2016, 18, 433-441.	2.9	22
28	Neuroimaging utilization and findings in headache outpatients: Significance of red and yellow flags. Cephalalgia, 2018, 38, 1841-1848.	1.8	18
29	Artificial Intelligence-Augmented Electrocardiogram Detection of Left Ventricular Systolic Dysfunction in the General Population. Mayo Clinic Proceedings, 2021, 96, 2576-2586.	1.4	15
30	Rationale and Therapeutic Opportunities for Natriuretic Peptide System Augmentation in Heart Failure. Current Heart Failure Reports, 2015, 12, 7-14.	1.3	13
31	Effect of integrated community neurology on utilization, diagnostic testing, and access. Neurology: Clinical Practice, 2017, 7, 306-315.	0.8	10
32	Sex-specific cut-off values for soluble suppression of tumorigenicity 2 (ST2) biomarker increase its cardiovascular prognostic value in the community. Biomarkers, 2021, 26, 639-646.	0.9	7
33	Impact of electronic clinical decision support on adherence to guideline-recommended treatment for hyperlipidaemia, atrial fibrillation and heart failure: protocol for a cluster randomised trial. BMJ Open, 2017, 7, e019087.	0.8	6
34	Can a Cardiac Peptide Predict Mortality in Human Hypertension?. Hypertension, 2011, 57, 670-671.	1.3	5
35	Myocardial Aging, the Cardiac Atria, and BNP. Journal of the American College of Cardiology, 2019, 74, 1801-1803.	1.2	5
36	Aged Mediated Cardiac Fibrosis and Diastolic Impairment Is Associated with a Reduction in the Collagen Degrading Pathway and an Imbalance between the Natriuretic Peptide and the Renin-Angiotensin-Aldosterone Systems. Journal of Cardiac Failure, 2013, 19, S1.	0.7	1

#	ARTICLE	IF	CITATIONS
37	MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results. BMC Pharmacology & Toxicology, 2015, 16, .	1.0	1
38	Synchronous neurologyâ€“primary care collaboration in a medical home. Neurology: Clinical Practice, 2020, 10, 388-395.	0.8	1
39	Relative Utility of Health ABC Risk Score, NT-proBNP and Systolic Function as Heart Failure Screening Tools in the General Community. Journal of Cardiac Failure, 2013, 19, S29.	0.7	0
40	Novel Protein Therapeutics for Human Preclinical Diastolic Dysfunction (Stage B Heart Failure): Chronic SQ BNP Administration. Journal of Cardiac Failure, 2013, 19, S65.	0.7	0
41	Differential Cardiac versus Renal Response to Acute Volume Overload in Human Preclinical Systolic Dysfunction and Renal Dysfunction with the Combination of PDEV Inhibition and BNP Administration. Journal of Cardiac Failure, 2014, 20, S13.	0.7	0
42	Pharmacokinetics of subcutaneous delivery of M-ANP: an innovative designer anp-based guanylyl cyclase activating peptide for hypertension. Journal of the American Society of Hypertension, 2014, 8, e33.	2.3	0
43	Abstract 17940: PDEV Inhibition + BNP Administration Enhanced the Cardiac but not the Renal Response to Acute Volume Overload in Human Preclinical Diastolic Dysfunction as Compared to PDEV Inhibition Alone. Circulation, 2014, 130, .	1.6	0